Literature DB >> 17031287

Safety of intravitreal injection of bevacizumab in rabbit eyes.

Leonard Feiner1, Emily E Barr, Ying-Bo Shui, Nancy M Holekamp, Milam A Brantley.   

Abstract

PURPOSE: To evaluate the safety of intravitreal injection of bevacizumab in rabbits using electrophysiological testing and histopathologic analysis.
METHODS: New Zealand albino rabbits were injected in one eye with control antibody (n = 2), 0.05 mL of bevacizumab (n = 3), or 0.2 mL of bevacizumab (n = 3). Electroretinograms were obtained 1 week and 4 weeks after injection. Histologic analysis was performed after completion of the electroretinographic studies.
RESULTS: No statistical differences were seen in scotopic and photopic a- and b-wave amplitudes between untreated control and bevacizumab-injected eyes. No histopathologic differences were identified between untreated control and bevacizumab-injected eyes.
CONCLUSION: Our study did not find evidence of retinal toxicity from a single intravitreal injection of bevacizumab in rabbits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031287     DOI: 10.1097/01.iae.0000230717.85319.f5

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  23 in total

1.  Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema.

Authors:  Abdullah Ozkiriş
Journal:  Doc Ophthalmol       Date:  2010-02-07       Impact factor: 2.379

2.  Short term apoptotic activity of intravitreal bevacizumab on rabbit retina.

Authors:  Fatih Mehmet Türkcü; Mehmet Numan Alp; Gül Türkcü; Sezer Kulaçoğlu; Gülcan Kural
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

3.  Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model.

Authors:  Ayhan Dursun; Mustafa Kemal Arici; Feyza Dursun; Ayse Vural Ozec; Mustafa Ilker Toker; Haydar Erdogan; Aysen Topalkara
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

4.  The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.

Authors:  Matthias Lüke; Kai Januschowski; Max Warga; Julia Beutel; Martin Leitritz; Faik Gelisken; Salvatore Grisanti; Toni Schneider; Christoph Lüke; Karl Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

5.  The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis.

Authors:  Priscilla K Brastianos; Harry C Brastianos; Wesley Hsu; Daniel M Sciubba; Thomas Kosztowski; Betty M Tyler; Violette Renard Recinos; Peter Burger; Stuart A Grossman
Journal:  J Neurooncol       Date:  2011-07-26       Impact factor: 4.130

6.  Effect of anti-VEGF antibody on retinal ganglion cells in rats.

Authors:  Aya Iriyama; Yi-Ning Chen; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

7.  Effects of anti-VEGF agents on rat retinal Müller glial cells.

Authors:  Bin Guo; Yingli Wang; Yannian Hui; Xinguang Yang; Qinhua Fan
Journal:  Mol Vis       Date:  2010-05-01       Impact factor: 2.367

8.  [Localisation of bevacizumab in the monkey retina after an intravitreal injection of Avastin].

Authors:  U Schraermeyer; P Heiduschka; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

9.  Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits.

Authors:  Saloomeh Saati; Rajat N Agrawal; Stan Louie; Gerald J Chader; Mark S Humayun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-31       Impact factor: 3.117

Review 10.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.